Adjuvant application of interferons.
el Kassas
H
H
Division of Medical Oncology, University of Pittsburgh Cancer Institute, PA, USA.
Kirkwood
J M
JM
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D004306:Dose-Response Relationship, Immunologic; D004338:Drug Combinations; D005260:Female; D005678:G(M2) Ganglioside / Q000627:therapeutic use; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000008:administration & dosage / Q000627:therapeutic use; D007376:Interleukin-2 / Q000008:administration & dosage; D008297:Male; D008545:Melanoma / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D015337:Multicenter Studies as Topic; D009367:Neoplasm Staging; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D018074:Vaccines, Conjugate / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D004338:Drug Combinations; D007370:Interferon Type I; D007376:Interleukin-2; D011994:Recombinant Proteins; D018074:Vaccines, Conjugate; D005678:G(M2) Ganglioside; D007371:Interferon-gamma